当前位置： SCI文献检索 > LEUKEMIA期刊下所有文献 > A phase I/II study of imatinib plus reinduction therapy for c-kit-positive relapsed/refractory acute myeloid leukemia: inhibition of Akt activation correlates with complete response.

A phase I/II study of imatinib plus reinduction therapy for c-kit-positive relapsed/refractory acute myeloid leukemia: inhibition of Akt activation correlates with complete response.

Abstract：

:This phase I/II study evaluated imatinib as a c-kit inhibitor combined with mitoxantrone, etoposide and cytarabine therapy for patients with primary refractory or relapsed c-kit+ acute myeloid leukemia (AML). Imatinib was escalated through three dose levels in successive six patient cohorts. The combination was well tolerated up to 400 mg/day imatinib. Of 21 patients treated at this dose, 13 (62%) achieved complete response (CR), 7 (33%) were non-responders and one died during induction. The CR rate was 80% in patients with standard-risk karyotype versus 33% in patients with adverse karyotype. The CR rate for primary non-responders was 6/14 (43%) versus 7/7 (100%) for relapsed patients. AML blasts from peripheral blood were assayed for phosphorylated Akt (pAkt) and phosphorylated ERK (pERK) by flow cytometry before to and after imatinib dosing. Of eight patients achieving CR with reinduction, seven demonstrated marked (≥60%) pAkt inhibition with imatinib therapy. In contrast, all the six non-responders to reinduction demonstrated <60% pAkt inhibition (P=0.005). There was no correlation between pERK inhibition and response to therapy. These results indicate that lack of pAkt inhibition in vivo is associated with resistance to reinduction therapy using this regimen. Further studies using agents that are able to inhibit Akt more effectively are warranted.

journal_name

Leukemia

journal_title

Leukemia

authors

Brandwein JM,Hedley DW,Chow S,Schimmer AD,Yee KW,Schuh AC,Gupta V,Xu W,Kamel-Reid S,Minden MD

doi

10.1038/leu.2011.34

subject

Has Abstract

pub_date

2011-06-01 00:00:00

pages

945-52

issue

6

eissn

0887-6924

issn

1476-5551

pii

leu201134

journal_volume

25

pub_type

杂志文章

相关文献

LEUKEMIA文献大全
  • Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment.

    abstract：:Tyrosine kinase inhibitors represent today's treatment of choice in chronic myeloid leukemia (CML). Allogeneic hematopoietic stem cell transplantation (HSCT) is regarded as salvage therapy. This prospective randomized CML-study IIIA recruited 669 patients with newly diagnosed CML between July 1997 and January 2004 fro...

    journal_title：Leukemia

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1038/leu.2015.281

    authors： Gratwohl A,Pfirrmann M,Zander A,Kröger N,Beelen D,Novotny J,Nerl C,Scheid C,Spiekermann K,Mayer J,Sayer HG,Falge C,Bunjes D,Döhner H,Ganser A,Schmidt-Wolf I,Schwerdtfeger R,Baurmann H,Kuse R,Schmitz N,Wehmeier A,

    更新日期：2016-03-01 00:00:00

  • Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): a multicenter study.

    abstract：:Myelodysplastic syndromes (MDS) with del(5q) are considered to have a benign course of the disease. In order to address the issue of the propensity of those patients to progress to acute myeloid leukemia (AML), data on 381 untreated patients with MDS and del(5q) characterized by low or intermediate I International Pro...

    journal_title：Leukemia

    pub_type： 杂志文章,多中心研究

    doi：10.1038/leu.2011.391

    authors： Germing U,Lauseker M,Hildebrandt B,Symeonidis A,Cermak J,Fenaux P,Kelaidi C,Pfeilstöcker M,Nösslinger T,Sekeres M,Maciejewski J,Haase D,Schanz J,Seymour J,Kenealy M,Weide R,Lübbert M,Platzbecker U,Valent P,Götze K,

    更新日期：2012-06-01 00:00:00

  • hNUDC promotes the cell proliferation and differentiation in a leukemic cell line via activation of the thrombopoietin receptor (Mpl).

    abstract：:We have recently identified a human homolog of a fungal nuclear migration protein (hNUDC) that binds specifically with the extracellular domain of thrombopoietin receptor (Mpl). Preliminary studies with human CD34(+) cells cultured in serum-free medium and normal mice showed that hNUDC appears to act as a cytokine, tr...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2008.20

    authors： Tang YS,Zhang YP,Xu P

    更新日期：2008-05-01 00:00:00

  • Blocking protein geranylgeranylation is essential for lovastatin-induced apoptosis of human acute myeloid leukemia cells.

    abstract：:Lovastatin is an inhibitor of the enzyme 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, the major regulatory enzyme of the mevalonate pathway. We have previously reported that lovastatin induces a significant apoptotic response in human acute myeloid leukemia (AML) cells. To identify the critical biochemic...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2402196

    authors： Xia Z,Tan MM,Wong WW,Dimitroulakos J,Minden MD,Penn LZ

    更新日期：2001-09-01 00:00:00

  • Reduced-intensity conditioning for acute myeloid leukemia: is this strategy correct.

    abstract：:Allogeneic stem cell transplantation for acute myeloid leukemia (AML) using reduced-intensity conditioning (RIC) is based on the strategy of attaining donor cell engraftment with immunosuppressive agents. This approach, which relies predominantly on donor effector cells for anti-leukemic or graft-versus-leukemia effec...

    journal_title：Leukemia

    pub_type： 杂志文章,评审

    doi：10.1038/sj.leu.2404328

    authors： Lazarus HM,Rowe JM

    更新日期：2006-10-01 00:00:00

  • Prediction of relapse by day 100 BCR-ABL quantification after allogeneic stem cell transplantation for chronic myeloid leukemia.

    abstract：:Chronic myeloid leukemia (CML) relapse after allogeneic stem cell transplantation (SCT) is a relatively frequent situation, which is correlated to disease status, time from diagnosis to transplant and T-cell depletion. We evaluated the potential for early minimal residual disease (MRD) BCR-ABL quantification to predic...

    journal_title：Leukemia

    pub_type： 临床试验,杂志文章

    doi：10.1038/sj.leu.2404170

    authors： Asnafi V,Rubio MT,Delabesse E,Villar E,Davi F,Damaj G,Hirsch I,Dhédin N,Vernant JP,Varet B,Buzyn A,Macintyre E

    更新日期：2006-05-01 00:00:00

  • Identification of a gene element essential for leukemia-specific expression of transgenes.

    abstract：:Leukemia-specific promoters and enhancers for gene therapy had never been reported. Since the Wilms' tumor gene WT1 is overexpressed in almost all types of leukemia, WT1 is an ideal target of leukemia-specific therapy. To explore the possibility of gene therapy for leukemia using WT1 promoter and enhancer, their activ...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2403260

    authors： Hosen N,Yanagihara M,Nakazawa T,Kanato K,Nishida S,Shirakata T,Asada M,Masuda T,Taniguchi Y,Kawakami M,Tsuboi A,Ikegame K,Oka Y,Ogawa H,Kawase I,Oji Y,Sugiyama H

    更新日期：2004-03-01 00:00:00

  • Hematopoietic growth factors in acute leukemia.

    abstract：:The hematopoietic growth factors are glycoproteins that can be produced by recombinant DNA technology. They have many potential clinical uses in acute leukemia; several areas have been explored extensively and much data are available from clinical trials. Other areas are of potential interest, but have a paucity of cl...

    journal_title：Leukemia

    pub_type： 杂志文章,评审

    doi：10.1038/sj.leu.2400592

    authors： Rowe JM,Liesveld JL

    更新日期：1997-03-01 00:00:00

  • B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches.

    abstract：:Despite considerable advances in the treatment of multiple myeloma (MM) in the last decade, a substantial proportion of patients do not respond to current therapies or have a short duration of response. Furthermore, these treatments can have notable morbidity and are not uniformly tolerated in all patients. As there i...

    journal_title：Leukemia

    pub_type： 杂志文章,评审

    doi：10.1038/s41375-020-0734-z

    authors： Shah N,Chari A,Scott E,Mezzi K,Usmani SZ

    更新日期：2020-04-01 00:00:00

  • Deletion of chromosome 2 is an early event in the development of radiation-induced myeloid leukemia in SJL/J mice.

    abstract：:In this study we have analyzed the chromosomal changes in the preleukemic phase in SJL/J mice treated with radiation and acute myeloid leukemias (AMLs) induced by radiation alone or with additional corticosteroid treatment. SJL/J mice exposed to 300 rad whole body irradiation developed a low incidence of AML (20-25%) ...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Trakhtenbrot L,Krauthgamer R,Resnitzky P,Haran-Ghera N

    更新日期：1988-08-01 00:00:00

  • Allogeneic haemopoietic transplantation for acute myeloid leukaemia in second complete remission: a registry report by the Acute Leukaemia Working Party of the EBMT.

    abstract：:Allogeneic haemopoietic cell transplant (allo-HCT) may be curative in acute myeloid leukaemia (AML) in second complete remission (CR2) but the impact of reduced intensity (RIC) versus myeloablative conditioning (MAC) is uncertain. The Acute Leukaemia Working Party of the European Society for Blood and Bone Marrow Tran...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/s41375-019-0527-4

    authors： Gilleece MH,Labopin M,Savani BN,Yakoub-Agha I,Socié G,Gedde-Dahl T,Blaise D,Byrne JL,Craddock C,Cornelissen JJ,Arcese W,Forcade E,Crawley C,Polge E,Mohty M,Nagler A

    更新日期：2020-01-01 00:00:00

  • Myeloablative therapy with blood stem cell transplantation is effective in mantle cell lymphoma.

    abstract：:Long-term disease-free survival following conventional cytotoxic therapy is extremely rare in patients with advanced-stage mantle cell lymphoma (MCL). High-dose conditioning therapy consisting of hyperfractionated total body irradiation (TBI, 14.4 Gy) and cyclophosphamide (200 mg/kg) was therefore offered to 13 patien...

    journal_title：Leukemia

    pub_type： 临床试验,杂志文章

    doi：

    authors： Haas R,Brittinger G,Meusers P,Murea S,Goldschmidt H,Wannenmacher M,Hunstein W

    更新日期：1996-12-01 00:00:00

  • Cloning and functional characterization of MEF2D/DAZAP1 and DAZAP1/MEF2D fusion proteins created by a variant t(1;19)(q23;p13.3) in acute lymphoblastic leukemia.

    abstract：:We analyzed the TS-2 acute lymphoblastic leukemia (ALL) cell line that contains a t(1;19)(q23;p13.3) but lacks E2A-PBX1 fusion typically present in leukemias with this translocation. We found that the t(1;19) in TS-2 fuses the 19p13 gene DAZAP1 (Deleted in Azoospermia-Associated Protein 1) to the 1q23 gene MEF2D (Myoc...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2403684

    authors： Prima V,Gore L,Caires A,Boomer T,Yoshinari M,Imaizumi M,Varella-Garcia M,Hunger SP

    更新日期：2005-05-01 00:00:00

  • Leukemic dendritic cells generated in the presence of FLT3 ligand have the capacity to stimulate an autologous leukemia-specific cytotoxic T cell response from patients with acute myeloid leukemia.

    abstract：:It has been proposed that adoptive immunotherapy, for the treatment of relapsed AML, with cytotoxic T lymphocytes which show a relative specificity for the leukemic cells may have the advantage of maximizing the beneficial anti-leukemic effect whilst minimizing the probability of graft-versus-host disease. In this stu...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2402013

    authors： Woiciechowsky A,Regn S,Kolb HJ,Roskrow M

    更新日期：2001-02-01 00:00:00

  • Determination of clonality in patients who present with diagnostic dilemmas: a laboratory experience and review of the literature.

    abstract：:Identification of rearrangements in the immunoglobulin heavy chain (IgH), T cell receptor (TCR) and other genes assists in the classification of hemopoietic disorders. This study reviews a 5 year experience of genotyping as an assessment of clonality in a central referral laboratory. Patients were referred for assessm...

    journal_title：Leukemia

    pub_type： 杂志文章,评审

    doi：10.1038/sj.leu.2400678

    authors： Rockman SP

    更新日期：1997-06-01 00:00:00

  • Quantitation of leukemia clone-specific antigen gene rearrangements by a single-step PCR and fluorescence-based detection method.

    abstract：:PCR-based detection of minimal residual disease (MRD) in children with precursor B cell acute lymphoblastic leukemia (pre-B ALL) by amplification of clone-specific antigen gene rearrangements has been labor-intensive. In this study we present a simpler, yet accurate, method to assess and quantitate MRD in pediatric pr...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2401530

    authors： Mayer SP,Giamelli J,Sandoval C,Roach AS,Fevzi Ozkaynak M,Tugal O,Rovera G,Jayabose S

    更新日期：1999-11-01 00:00:00

  • Expression of endothelial cell-associated molecules in AML cells.

    abstract：:Recently, it has been clarified that interaction between hematopoietic cells and endothelial cells is important in normal hematopoiesis and leukemogenesis. In this study, we examined the relationship between AML cells and endothelial cells by analyzing the expression profile of angiogenic factors, angiopoietin-1 (Ang-...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2402326

    authors： Watarai M,Miwa H,Shikami M,Sugamura K,Wakabayashi M,Satoh A,Tsuboi K,Imamura A,Mihara H,Katoh Y,Kita K,Nitta M

    更新日期：2002-01-01 00:00:00

  • Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera.

    abstract：:After accounting for misdiagnosis and treatment effect, allele-specific (AS)-PCR detects the JAK2V617F mutation in >95% of polycythemia vera (PV) patients. Using database inquiry, we identified 6 of a total 220 cases with PV that were JAK2V617F-negative (prevalence=3%). Of these, five cases ( approximately 80%) were f...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2404810

    authors： Pardanani A,Lasho TL,Finke C,Hanson CA,Tefferi A

    更新日期：2007-09-01 00:00:00

  • Increased expression of CD152 (CTLA-4) by normal T lymphocytes in untreated patients with B-cell chronic lymphocytic leukemia.

    abstract：:Patients with chronic lymphocytic leukemia (CLL) have defects in both cellular and humoral immunity. Since CD152 (CTLA-4) plays a critical role in downregulating T-cell responses, we studied the expression of surface and cytoplasmic CD152 (sCD152 and cCD152, respectively) in freshly isolated T cells from treatment-naï...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2403907

    authors： Motta M,Rassenti L,Shelvin BJ,Lerner S,Kipps TJ,Keating MJ,Wierda WG

    更新日期：2005-10-01 00:00:00

  • JAK inhibitors suppress t(8;21) fusion protein-induced leukemia.

    abstract：:Oncogenic mutations in components of the JAK/STAT pathway, including those in cytokine receptors and JAKs, lead to increased activity of downstream signaling and are frequently found in leukemia and other hematological disorders. Thus, small-molecule inhibitors of this pathway have been the focus of targeted therapy i...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2013.197

    authors： Lo MC,Peterson LF,Yan M,Cong X,Hickman JH,Dekelver RC,Niewerth D,Zhang DE

    更新日期：2013-12-01 00:00:00

  • Anaplastic large cell lymphomas expressing the novel chimeric protein p80NPM/ALK: a distinct clinicopathologic entity.

    abstract：:Some anaplastic large cell lymphomas (ALCLs) carry a specific chromosomal translocation, t(2;5)(p23;q35). Recently, we found a novel hyperphosphorylated 80-kDa protein tyrosine kinase, p80, in ALCLs with t(2;5). Subsequent cDNA cloning revealed p80 to be a fusion protein of two genes, the novel tyrosine kinase gene an...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Shiota M,Mori S

    更新日期：1997-04-01 00:00:00

  • Monitoring of WT1 expression in PB and CD34(+) donor chimerism of BM predicts early relapse in AML and MDS patients after hematopoietic cell transplantation with reduced-intensity conditioning.

    abstract：:Relapse of malignant disease remains the major complication in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) after hematopoietic cell transplantation (HCT) with reduced-intensity conditioning (RIC). In this study, we investigated the predictive value of disease-specific markers (DSMs), d...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2010.283

    authors： Lange T,Hubmann M,Burkhardt R,Franke GN,Cross M,Scholz M,Leiblein S,Al-Ali HK,Edelmann J,Thiery J,Niederwieser D

    更新日期：2011-03-01 00:00:00

  • The diagnositc significance of Myf-3 hypermethylation in malignant lymphoproliferative disorders.

    abstract：:Deregulated methylation of cytosine in DNA is a frequent finding in malignancy that is reflected by general genomic hypomethylation and regional hypermethylation that includes the myogenic gene Myf-3. In this study of 198 DNA samples from 186 patients with a wide range of lymphoproliferative disorders (LPD), the methy...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2402080

    authors： Taylor JM,Kay PH,Spagnolo DV

    更新日期：2001-04-01 00:00:00

  • CAR T-cells targeting FLT3 have potent activity against FLT3-ITD+ AML and act synergistically with the FLT3-inhibitor crenolanib.

    abstract：:FMS-like tyrosine kinase 3 (FLT3) is a transmembrane protein expressed on normal hematopoietic stem and progenitor cells (HSC) and retained on malignant blasts in acute myeloid leukemia (AML). We engineered CD8+ and CD4+ T-cells expressing a FLT3-specific chimeric antigen receptor (CAR) and demonstrate they confer pot...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/s41375-018-0009-0

    authors： Jetani H,Garcia-Cadenas I,Nerreter T,Thomas S,Rydzek J,Meijide JB,Bonig H,Herr W,Sierra J,Einsele H,Hudecek M

    更新日期：2018-05-01 00:00:00

  • The biological consequences of excess GM-CSF levels in transgenic mice also lacking high-affinity receptors for GM-CSF.

    abstract：:GM-CSF transgenic mice were crossed with mice with homozygous inactivation of the gene encoding the common beta chain (beta c) of the GM-CSF receptor to produce mice with constitutively elevated GM-CSF levels but no high-affinity GM-CSF receptors. GM-CSF transgenic beta c -/- mice had exceptionally elevated serum GM-C...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2400926

    authors： Metcalf D,Mifsud S,Di Rago L,Robb L,Nicola NA,Alexander W

    更新日期：1998-03-01 00:00:00

  • Results of the first randomized multicentre trial on childhood acute lymphoblastic leukaemia in Russia.

    abstract：:Until 1990, the survival of children with acute lymphoblastic leukaemia (ALL) in Russia was below 10%. To establish a protocol feasible under conditions there, ALL-MB 91 was designed to avoid prolonged bone marrow aplasia, thereby reducing needs for extensive supportive care, blood transfusions, long-lasting hospitali...

    journal_title：Leukemia

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1038/leu.2008.63

    authors： Karachunskiy A,Herold R,von Stackelberg A,Miakova N,Timakow A,Mahortih T,Bajdun L,Maschan A,Fechina L,Shamardina A,Dudkin S,Lebedev V,Varfolomeeva S,Timofeeva V,Roumiantseva J,Chipsanova N,Rumjanzew A,Henze G

    更新日期：2008-06-01 00:00:00

  • Two acute monocytic leukemia (AML-M5a) cell lines (MOLM-13 and MOLM-14) with interclonal phenotypic heterogeneity showing MLL-AF9 fusion resulting from an occult chromosome insertion, ins(11;9)(q23;p22p23).

    abstract：:We describe two new human leukemia cell lines, MOLM-13 and MOLM-14, established from the peripheral blood of a patient at relapse of acute monocytic leukemia, FAB M5a, which had evolved from myelodysplastic syndrome (MDS). Both cell lines express monocyte-specific esterase (MSE) and MLL-AF9 fusion mRNA. Gene fusion is...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2400768

    authors： Matsuo Y,MacLeod RA,Uphoff CC,Drexler HG,Nishizaki C,Katayama Y,Kimura G,Fujii N,Omoto E,Harada M,Orita K

    更新日期：1997-09-01 00:00:00

  • Configuration of the immunoglobulin and T cell receptor gene regions in hairy cell leukemia and B-chronic lymphocytic leukemia.

    abstract：:The configuration of the immunoglobulin heavy and light chain genes and of the T cell receptor (TCR) beta region was examined in a series of patients with hairy cell leukemia (HCL) and compared with the findings in B cell chronic lymphocytic leukemia (B-CLL). In all cases of HCL and B-CLL studied a rearrangement of th...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Migone N,Giubellino MC,Casorati G,Tassinari A,Lauria F,Foa R

    更新日期：1987-04-01 00:00:00

  • The role of TGFβ in hematopoiesis and myeloid disorders.

    abstract：:The role of transforming growth factor-β (TGFβ) signaling in embryological development and tissue homeostasis has been thoroughly characterized. Its canonical downstream cascade is well known, even though its true complexity and other non-canonical pathways are still being explored. TGFβ signaling has been described a...

    journal_title：Leukemia

    pub_type： 杂志文章,评审

    doi：10.1038/s41375-019-0420-1

    authors： Bataller A,Montalban-Bravo G,Soltysiak KA,Garcia-Manero G

    更新日期：2019-05-01 00:00:00

  • Potential antileukemic effect of gamma delta T cells in acute lymphoblastic leukemia.

    abstract：:The immune response to leukemia is poorly understood. We postulated that nonmalignant T lymphocytes remaining within bone marrow from children with newly diagnosed ALL could be involved in this immune response. T lymphocytes which expressed gamma delta TCR comprised less than 1% of ALL marrow cells. A preferential out...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Duval M,Yotnda P,Bensussan A,Oudhiri N,Guidal C,Rohrlich P,Boumsell L,Grandchamp B,Vilmer E

    更新日期：1995-05-01 00:00:00